… American College of Rheumatology (ACR) 20 (panel A), ACR 50 (panel B), and ACR 70 (panel
C) responses over 1 year in all patients who received at least 1 dose of the study …

Background Some children with juvenile idiopathic arthritis either do not respond, or are
intolerant to, treatment with disease-modifying antirheumatic drugs, including anti-tumour …

Objectives This phase III study evaluated the efficacy and safety of rituximab plus methotrexate
(MTX) in patients with active rheumatoid arthritis (RA) who had an inadequate response …

… Since the report of DAH without hemoptysis by Abud-Mendoza et al. in 1985 [26], most of
the series have confirmed the irregular presentation of this symptom (30–100%) [36, 38]. …

… Numbers at the far right of the line graphs in A and C and numbers inside the bar graphs in
B and D are the actual percentages that are represented graphically. ∗︁ = P < 0.05; + = P < …

… The factors associated with a higher risk of infection were: mechanical ventilation,
hypocomplementemia and high C-reactive protein levels. In contrast, in patients who had had no …

Regulatory T cells have an important role in the control of self-reactivity, and in the
pathogenesis of autoimmune inflammatory conditions. The aim of this work was to perform a …

… In brief, PBMNCs were incubated with a biotinylated antibody cocktail for 15 minutes at 4C,
washed, incubated with anti-Biotin Micro Beads (Miltenyi) for 20 minutes at 4C and washed. …

Objectives To assess the efficacy and safety of switching from the infliximab reference
product (RP; Remicade) to its biosimilar CT-P13 (Remsima, Inflectra) or continuing CT-P13 in …

Aim: To identify periodontal bacterial DNA (PBDNA) by PCR in subgingival dental plaque (SDP),
serum and synovial fluid (SF) of rheumatoid arthritis (RA) with periodontal disease (PD) …